Next-generation sequencing (NGS) can help pharmaceutical and biotech researchers better understand the genetic variants associated with various diseases. These insights can support the development of targeted therapeutics and multi-analyte tumor analysis. NGS also opens the door for discovery of novel methods to monitor cancer treatment and recurrence.
lllumina brings innovation to drug development by offering comprehensive genomic solutions working in collaboration with leading pharmaceutical providers.
As targeted therapies make their way through pharmaceutical pipelines, the need for companion diagnostics is increasing.
Learn MoreNGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.
Learn MoreUnderstand how variations in the human genome affect our response to medications. Pharmacogenomics (PGx) research can ultimately help maximize the benefits of treatment plans while reducing health care costs.
Learn More About PGxA groundbreaking international clinical study has succeeded in integrating imaging, multiomic technologies, and data analysis into a powerful drug discovery engine. The Global Genomics Group (G3) has demonstrated the value of its novel approach, with the introduction of a new diagnostic and several drug candidates in development with pharmaceutical partners.
Read ArticleTargeted drug discovery has traditionally focused on inhibiting or modulating the function of abnormal proteins. But diseases could also potentially be treated in the future by controlling gene expression. In this podcast episode, Dr. Eric R. Olson of Syros Pharmaceuticals explains how epigenomics is enabling a paradigm shift in drug discovery.
Listen to the PodcastGarret Hampton, EVP of Clinical Genomics at Illumina, shares his vision for how genomics might shape the future of oncology.
Polygenic risk scores represent the total number of genetic variants that an individual has to assess their heritable risk of developing a particular disease.
Complex diseases are caused by a combination of genetic and environmental factors. Luckily, genomics technologies are helping accelerate research, and, hopefully one day, the diagnosis, treatment, and prevention of these diseases.
Access resources to explore NGS-based biomarker discovery and profiling.
Regeneron discusses their latest work and overall mission to explore new variations in genomes that can help explain disease.
Chan Zuckerberg Biohub discuss their mission to conduct innovative experiments and new kinds of collaborations in genomics.
Read how Merck Serono uses NGS for cell line stability testing and biosafety monitoring.